AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
Koenig KL, Sahasrabudhe KD, Sigmund AM, Bhatnagar B.
Genes (Basel). 2020 Jul 24;11(8):845. doi: 10.3390/genes11080845.
The International Consensus Classification of acute myeloid leukemia.
Weinberg OK, Porwit A, Orazi A, Hasserjian RP, Foucar K, Duncavage EJ, Arber DA.
Virchows Arch. 2023 Jan;482(1):27-37. doi: 10.1007/s00428-022-03430-4. Epub 2022 Oct 20.
CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O'Nions J, Coats T, Nagumantry S, Hodgson K, Whitmill R, Amott I, Flynn G, Taussig D, Zhao R, Cunningham N, Roset M, Cuadras D, Medalla G, Kuter H, Park S, Legg A, Khan AB.
Br J Haematol. 2024 Oct;205(4):1326-1336. doi: 10.1111/bjh.19622. Epub 2024 Jul 8.
What is new in acute myeloid leukemia classification?
Park HS.
Blood Res. 2024 Apr 15;59(1):15. doi: 10.1007/s44313-024-00016-8.
Acute Myeloid Leukemia with Myelodysplasia Related Changes.
Shibusawa M, Tanimoto T.
In: Li W, editor. Leukemia [Internet]. Brisbane (AU): Exon Publications; 2022 Oct 16. Chapter 6.
Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needle.
Phillips DF, Zeidner JF.
Expert Opin Emerg Drugs. 2021 Sep;26(3):245-257. doi: 10.1080/14728214.2021.1950689. Epub 2021 Jul 6.
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE, Lancet JE.
Blood Adv. 2021 Mar 23;5(6):1719-1728. doi: 10.1182/bloodadvances.2020003510.
[AML with myelodysplasia-related changes complicating xeroderma pigmentosum].
Darfaoui L, Idrissi SA, Quiddi W, Sayagh S.
Ann Biol Clin (Paris). 2023 May 16;81(2):219-221. doi: 10.1684/abc.2023.1799.
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Rautenberg C, Stölzel F, Röllig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, Verbeek M, Unglaub JM, Thol F, Krause SW, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Severmann J, Wass M, Fransecky L, Chemnitz J, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Koch K, Henning L, Kobbe G, Haas R, Alakel N, Röhnert MA, Sockel K, Hanoun M, Platzbecker U, Holderried TAW, Morgner A, Heuser M, Sauer T, Götze KS, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Schroeder T, Middeke JM.
Blood Cancer J. 2021 Oct 4;11(10):164. doi: 10.1038/s41408-021-00558-5.
CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis.
Renga G, Nunzi E, Stincardini C, Pariano M, Puccetti M, Pieraccini G, Di Serio C, Fraziano M, Poerio N, Oikonomou V, Mosci P, Garaci E, Fianchi L, Pagano L, Romani L.
Blood. 2024 Apr 18;143(16):1628-1645. doi: 10.1182/blood.2023021380.
